

AUG. 4. 2004 3:12PM

AVENTIS US PAT DEPT

RECEIVED  
CENTRAL FAX CENTER  
AUG 04 2004

NO 6052 P  
**OFFICIAL**

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE


Applicants Docket Number:  
2501 US CNT

Applicants:  
Constantin Agouridas, et al

Serial No.  
10/075,635

Filing Date:  
February 13, 2002

Title of Invention:  
2-Halogenated Derivatives Of 5-O-Desosmaninyl-Erythronolide A,  
Their Preparation Process And Their Antibiotic Use

CERTIFICATE OF TRANSMISSION	
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 872-9306, on 8/4/04	
Date of Deposit	8/4/04
Printed Name of Person Signing Certificate Maribel Mendez	
Signature	

Total Number of Pages Sent: 7

Attorney: Balaram Gupta

Group Art Unit: 1624  
Examiner: Coleman, Brenda Libby

TO: Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

<input type="checkbox"/> Amendment, 37 CFR _____	<input type="checkbox"/> Fee Transmittal
<input type="checkbox"/> Charge deposit account, in duplicate	<input type="checkbox"/> Petition under 37 CFR _____
<input type="checkbox"/> Extension of Time Petition	<input type="checkbox"/> Other _____
<input type="checkbox"/> Issue Fee Transmittal & Advance Order	<input checked="" type="checkbox"/> Other <u>Amendment Pursuant to 37 C.F.R. §1.121 and Reply Pursuant to 37 C.F.R. § 1.111 (6 pgs.)</u>
<input type="checkbox"/> Maintenance Fee Transmittal	

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com  
NOTICE: The documents accompanying this telexopy transmission are intended only for the use of the individual or entity named above. If you have received this telexopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

RECEIVED  
CENTRAL FAX CENTER

**OFFICIAL**

AUG 04 2004

**PATENT**

Docket No.: 2501 US CNT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Constantin Agouridas, et al.**

Examiner: Coleman, Brenda Libby

Serial No.: 10/075,635

Art Unit: 1624

Filed: February 13, 2002

**TELEFAX CERTIFICATE**

Title: **2-Halogenated Derivatives of 5-O-Desosmaninyl-Erythronolide A, Their Preparation Process and Their Antibiotic Use**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, at (703) 372-9306 on

*8/4/04*  
Date of transmission

*Brenda Libby Meadz*  
Signature

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

**AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY**

**PURSUANT TO 37 C.F.R. § 1.111**

Sir:

This is a Rule 111 Amendment in the above-identified patent application in response to the Office Action, paper no. 3, dated, May 4, 2004, having a response due by, August 4, 2004. It is respectfully requested that the following amendments and remarks be entered in this case.

**Request to Change Docket Number**

Applicants respectfully submit that the docket number used in the instant case has been changed from "146.1327-CON" to "2501 US CNT". Accordingly, Applicants respectfully request the Examiner to enter this change into the record and to use the new docket number in all of the future Office Actions in this case.